Joseph J. Ferra Jr. - 16 Mar 2024 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Robert Yang, Attorney-in-Fact
Issuer symbol
ELEV
Transactions as of
16 Mar 2024
Net transactions value
-$20,953
Form type
4
Filing time
19 Mar 2024, 16:10:08 UTC
Previous filing
20 Feb 2024
Next filing
18 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELEV Common Stock Options Exercise +12,562 +16% 90,453 16 Mar 2024 Direct F1
transaction ELEV Common Stock Tax liability $20,953 -4,773 -5.3% $4.39 85,680 16 Mar 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Restricted Stock Unit Options Exercise $0 -12,562 -17% $0.000000 62,809 16 Mar 2024 Common Stock 12,562 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2 25% of the RSUs vested on June 16, 2022, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3 The RSUs do not expire; they either vest or are canceled prior to the vesting date.